Akebia Therapeutics

Akebia Therapeutics is a fully integrated renal biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on addressing complications of chronic kidney disease through innovative small-molecule therapeutics. The company leverages proprietary hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) technology to develop oral alternatives to injectable treatments, with two FDA-approved commercial products and late-stage pipeline programs in global development.